Popular diabetes and obesity drugs also protect kidneys, study shows

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and without diabetes. The findings were published in The Lancet Diabetes & Endocrinology.

Facebook Comments